The global bleeding disorder treatment market is anticipated to grow at a CAGR of around 7.8% from 2020 to 2027 and expected to reach the market value of around US$ 20.5 Bn by 2027.
The term "bleeding disorders" refers to a category of problems that occur when the blood does not clot properly. While it is relatively rare, hemophilia is probably the most well-known hereditary bleeding condition. Males are particularly affected by this condition. Furthermore, many suffer from von Willebrand disease, the most common hereditary bleeding condition in the US that is caused by clotting proteins. Both men and women are susceptible to the disease. The most common cause of bleeding disorders is platelet deficiency, which is commonly acquired rather than hereditary. According to the National Hemophilia Foundation, there are 30,000-33,000 individuals in the US who have hemophilia.
Big calls for "replacement therapy"
Replacement therapy is the most common treatment for bleeding disorders. To avoid bleeding, patients may seek replacement therapy on a regular basis. This is known as prophylactic (PRO-fih-lac-tik) or preventive (PRO-fih-lac-tik) therapy. This replacement therapy can be provided to combat a bleeding episode that is in the progression stage, according to the Mayo Foundation for Medical Education and Research (MFMER). The use of "Antifibrinolytic Medicines" is yet another treatment option for bleeding disorders. Replacement therapy can be combined with antifibrinolytic medications (such as "tranexamic acid" and "epsilon aminocaproic acid"). It is given in the form of a tablet, which helps to prevent blood clots from breaking down. In the global bleeding disorder treatment market, replacement therapy with clotting factor replacement has also gained a lot of attention. Clotting factor replacement therapy can treat or avoid bleeding episodes by avoiding excessive blood loss and complications associated with bleeding, such as muscle, joint, and organ injury.
Research and development activities bolster the growth of global bleeding disorder treatment market
Gene therapy aims to provide long-term expression of a missing or abnormal coagulation factor at adequate and consistent levels, reducing or even eliminating the need for exogenous factor replacement. A recombinant adeno-associated virus (rAAV) vector to deliver the coagulation factor gene to the patient's liver has gained strong attention. Apart from that, the National Hemophilia Foundation reports that gene therapy has been one of the most sought-after therapies for hemophilia since decades. Replacement of a faulty gene with a functional one to generate enough clotting factor to short-circuit bleeds in a one-shot operation that could repair the hereditary disease as its source. Several companies plan to obtain US Food and Drug Administration (USFDA) approval to sell gene therapy in the coming years, as the procedure has gained considerable interest in the global market.
Government in alliance with prominent players assists in treatment of bleeding disorder in patients
The World Federation of Hemophilia (WFH) advocates for patients with hemophilia and von Willebrand disease (VWD), as well as women with bleeding disorders. The WFH Humanitarian Aid Program aims to improve access to care and treatment for people with hereditary bleeding disorders in developing countries by providing much-needed assistance. The WFH Humanitarian Aid Program ensures that patients have secure and timely access to treatment and care by providing a more stable and sustainable flow of humanitarian aid donations. It boosts future development by forming an alliance with influential players such as Sanofi, Genzyme, and Sobi, Grifols and Roche, CSL Behring, and Bayer.
Bleeding disorder treatment market is segmented based on type and drug class. By type, the market is segmented as hemophilia A, hemophilia B, and Von Willebrand Disease (vWD). Based on drug class, the market is segmented as plasma derived coagulation factor concentrates, recombinant coagulation factor concentrate, and others.
Based on type, hemophilia A will hold dominating share for the global bleeding disorder treatment market in the forecast period. Rising prevalence of bleeding disorder and increasing severity with the genetic evolution worldwide is expected to drive the bleeding disorder treatment market globally. Hemophilia A affects 12 per 100,000 males in the United States, according to the Centers for Disease Control and Prevention (CDC). Every year, approximately 400 boys are born with Hemophilia A. Apart from that, the availability of many treatment options in the global market contributes to the growth of the bleeding disorder treatment market.
According to the data revealed by the National Hemophilia Foundation, the main medication to treat hemophilia A is concentrated FV111 product, called clotting factor or simply factor. While plasma-derived FV111 products are still available, approx 75% of the hemophilia community takes a recombinant FV111 product.
Further, by drug class segment, recombinant coagulation factor concentrates will record a remarkable share for the growth of global bleeding disorder treatment market. As per the data revealed by the Food and Drug Administration (FDA), recombinant coagulation factor concentrates control bleeding in patients aged 12 years and older with hemophilia A or B with inhibitors. In May 2020, FDA approved Coagulation Factor VIIa (Recombinant)-jncw for Hemophilia. The approval is based on data from a clinical study evaluating coagulation factor VIIa (recombinant)-jncw in 27 patients with hemophilia A or B with inhibitors who had experienced a total of 465 mild or moderate bleeding episodes and three severe bleeding episodes. Approx. 86% of mild or moderate bleeding episodes were treated successfully with both lower and higher doses (75 mcg/kg and 225 mcg/kg) of coagulation factor VIIa (recombinant)-jncw, and all three severe bleeding episodes were treated successfully with the higher dose. This is considered as one of the prominent factors that contribute for the growth of global bleeding disorder treatment market.
In the coming years, North America is predicted to dominate the bleeding disorder treatment industry. Favorable reimbursement policies, in combination with healthcare benefits, as well as a broad patient population suffering from bleeding disorders, are driving the demand for bleeding disorder treatment globally. Asia-Pacific, on the other hand, is expected to witness a substantial CAGR in the coming years as a result of increased awareness of bleeding disorders and treatment options, which is driving the global bleeding disorder treatment market. Furthermore, the government initiative to improve healthcare infrastructure has a positive impact on the industry's growth of bleeding disorder treatment.
Prominent players for bleeding disorder treatment market involve Sanofi SA, Swedish Orphan Biovitrum AB, Janssen Pharmaceuticals, Inc., Baxter International Inc., Pfizer Inc., Genentech, Inc., CSL Behring, Novo Nordisk, and among others
Market By Type
Von Willebrand Disease (vWD)
Market By Drug Class
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrate
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Bleeding disorder treatment market is expected to reach a market value of around US$ 20.5 Bn by 2027.
The bleeding disorder treatment market is expected to grow at a CAGR of around 7.8% from 2020 to 2027.
Based on type, Hemophilia A is the leading segment in the overall market.
Research and development activity is one of the prominent factors that drive the demand for bleeding disorder treatment market.
Sanofi SA, Swedish Orphan Biovitrum AB, Janssen Pharmaceuticals, Inc., Baxter International Inc., Pfizer Inc., Genentech, Inc., CSL Behring, Novo Nordisk, and among others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years